Palladium Rallies: Up 3.9% on Strong Euro

Source: Dow Jones Newswires, Rhiannon Hoyle (12/13/10)

"The metal is supported by strong auto data out of China."

Palladium is surging in a broad-based commodity rally Monday, trading up 3.9% on a falling U.S. dollar and strengthening fundamentals.

At 1554 GMT, spot palladium traded at $760 a troy ounce—just 2% off its decade high of $776/oz. It recently reached an intraday high of $763.50/oz as the euro jumped against the dollar.

The metal, used widely in vehicle autocatalysts, is finding itself well-supported by strong auto data out of China, a senior London analyst said. Last week the China Association of Automobile Manufacturers announced total auto sales in the country, the world's largest auto market, rose to 1.697 million units in November, up 26.9% compared with a year earlier.

Vehicles in China are mainly gasoline-powered, which use palladium for catalysts instead of platinum, which is much costlier at $1,698/oz.

"We expect that recovering global automobile demand will likely continue to put upward pressure on autocatalyst demand and therefore on platinum and palladium prices," Goldman Sachs said in a report Monday.

Palladium and sister metal silver—which is up 3.4% at $29.614/oz—remain "the precious metals of the hour," German bank Commerzbank said in a daily note.

Palladium is seen as a favorite among the metals for its tightening fundamentals, and in particular fears that Russia, the world's largest producer, has exhausted state stockpiles.

UBS analyst Edel Tully said were there no Russian state reserve deliveries in 2011, market players could likely see prices rally toward $1,000/oz.

Flows into exchange-traded funds have also been strong in recent months, market participants said.

In the week to Dec. 10, palladium holdings in the exchange-traded fund of Zurich Cantonal Bank jumped 5.3%, or 22,461 ounces, to 450,262 ounces, the bank said Monday.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.